Bris­tol My­ers gets its first GI drug ap­proval, and it comes from a long­time Cel­gene MS pro­gram

A for­mer long­time Cel­gene pro­gram that saw a bumpy road to ap­proval has picked up a new OK, with its new own­ers at Bris­tol My­ers Squibb shep­herd­ing it to a win in ul­cer­a­tive col­i­tis.

The FDA ap­proved ozan­i­mod in UC on Thurs­day af­ter­noon, Bris­tol My­ers an­nounced, be­com­ing what the Big Phar­ma said is the first S1P re­cep­tor mod­u­la­tor to treat the dis­ease. The drug will use the same brand name of Zeposia as in its orig­i­nal in­di­ca­tion of mul­ti­ple scle­ro­sis in the re­lapsed set­ting. Thurs­day’s ap­proval al­so marks Bris­tol My­ers’ first GI drug to hit the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER